Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Vaccines

Free Subscription Articles published in J Virol Retrieve available abstracts of 170 articles: HTML format

Single Articles

April 2024
1. FAN Y-C, Chen J-M, Chen Y-Y, Ke Y-D, et al
   Epitope(s) involving amino acids of the fusion loop of Japanese encephalitis virus envelope protein is(are) important to elicit protective immunity.
   J Virol. 2024;98:e0177323.
   PubMed     Abstract available
   
   
   
2. TANG X, Li S, Zhou J, Bian X, et al
   Recombinant bivalent subunit vaccine combining truncated VP4 from P[7] and P[23] induces protective immunity against prevalent porcine rotaviruses.
   J Virol. 2024 Apr 9:e0021224. doi: 10.1128/jvi.00212.
   PubMed     Abstract available
   
   
   
3. QUADIRI A, Prakash S, Dhanushkodi NR, Singer M, et al
   Therapeutic prime/pull vaccination of HSV-2-infected guinea pigs with the ribonucleotide reductase 2 (RR2) protein and CXCL11 chemokine boosts antiviral local tissue-resident and effector memory CD4(+) and CD8(+) T cells and protects against recurrent
   J Virol. 2024 Apr 8:e0159623. doi: 10.1128/jvi.01596.
   PubMed     Abstract available
   
   
   
4. MANTEL N, Piras-Douce F, Chautard E, Marcos-Lopez E, et al
   Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination.
   J Virol. 2024 Apr 3:e0151623. doi: 10.1128/jvi.01516.
   PubMed     Abstract available
   
   
   
5. BRUNET J, Choucha Z, Gransagne M, Tabbal H, et al
   A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.
   J Virol. 2024 Apr 2:e0169323. doi: 10.1128/jvi.01693.
   PubMed     Abstract available
   
   
   
6. NAMBULLI S, Escriou N, Rennick LJ, Demers MJ, et al
   A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.
   J Virol. 2024 Apr 2:e0176223. doi: 10.1128/jvi.01762.
   PubMed     Abstract available
   
   
   March 2024
7. WU K, Hou YJ, Makrinos D, Liu R, et al
   Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults.
   J Virol. 2024 Mar 25:e0160323. doi: 10.1128/jvi.01603.
   PubMed     Abstract available
   
   
   
8. NUNBERG JH, Westover JB, York J, Jung KH, et al
   Restoration of virulence in the attenuated Candid#1 vaccine virus requires reversion at both positions 168 and 427 in the envelope glycoprotein GPC.
   J Virol. 2024 Mar 20:e0011224. doi: 10.1128/jvi.00112.
   PubMed     Abstract available
   
   
   
9. MAI F, Bergmann W, Reisinger EC, Muller-Hilke B, et al
   The varying extent of humoral and cellular immune responses to either vector- or RNA-based SARS-CoV-2 vaccines persists for at least 18 months and is independent of infection.
   J Virol. 2024 Mar 19:e0191223. doi: 10.1128/jvi.01912.
   PubMed     Abstract available
   
   
   February 2024
10. GEORGANA I, Scutts SR, Gao C, Lu Y, et al
    Filamin B restricts vaccinia virus spread and is targeted by vaccinia virus protein C4.
    J Virol. 2024 Feb 27:e0148523. doi: 10.1128/jvi.01485.
    PubMed     Abstract available
    
    
    
11. JOSHI VR, Claiborne DT, Pack ML, Power KA, et al
    A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope.
    J Virol. 2024 Feb 27:e0172023. doi: 10.1128/jvi.01720.
    PubMed     Abstract available
    
    
    
12. ISHIYAMA R, Yoshida K, Oikawa K, Takai-Todaka R, et al
    Production of infectious reporter murine norovirus by VP2 trans-complementation.
    J Virol. 2024;98:e0126123.
    PubMed     Abstract available
    
    
    
13. NIE L, Huang Y, Cheng Z, Luo H, et al
    An intranasal influenza virus vector vaccine protects against Helicobacter pylori in mice.
    J Virol. 2024 Feb 15:e0192323. doi: 10.1128/jvi.01923.
    PubMed     Abstract available
    
    
    
14. KATAYAMA M, Murakami S, Ishida H, Matsugo H, et al
    Antigenic commonality and divergence of hemagglutinin-esterase-fusion protein among influenza D virus lineages revealed using epitope mapping.
    J Virol. 2024 Feb 12:e0190823. doi: 10.1128/jvi.01908.
    PubMed     Abstract available
    
    
    
15. SHINGAI M, Iida S, Kawai N, Kawahara M, et al
    Extraction of the CDRH3 sequence of the mouse antibody repertoire selected upon influenza virus infection by subtraction of the background antibody repertoire.
    J Virol. 2024 Feb 7:e0199523. doi: 10.1128/jvi.01995.
    PubMed     Abstract available
    
    
    
16. BRICKER TL, Joshi A, Soudani N, Scheaffer SM, et al
    Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters.
    J Virol. 2024 Feb 2:e0120623. doi: 10.1128/jvi.01206.
    PubMed     Abstract available
    
    
    
17. ANDERSON EM, Coller B-AG
    Translational success of fundamental virology: a VSV-vectored Ebola vaccine.
    J Virol. 2024 Feb 2:e0162723. doi: 10.1128/jvi.01627.
    PubMed     Abstract available
    
    
    
18. LI H, Sun H, Tao M, Han Q, et al
    Recombinant parainfluenza virus 5 expressing clade 2.3.4.4b H5 hemagglutinin protein confers broad protection against H5Ny influenza viruses.
    J Virol. 2024 Feb 2:e0112923. doi: 10.1128/jvi.01129.
    PubMed     Abstract available
    
    
    
19. HSIEH M-S, Hsu C-W, Liao H-C, Lin C-L, et al
    SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters.
    J Virol. 2024 Feb 1:e0154623. doi: 10.1128/jvi.01546.
    PubMed     Abstract available
    
    
    January 2024
20. ROWE T, Davis W, Wentworth DE, Ross T, et al
    Differential interferon responses to influenza A and B viruses in primary ferret respiratory epithelial cells.
    J Virol. 2024 Jan 31:e0149423. doi: 10.1128/jvi.01494.
    PubMed     Abstract available
    
    
    
21. MU S, Chen L, Dong H, Li S, et al
    Enhanced antigen-specific CD8 T cells contribute to early protection against FMDV through swine DC vaccination.
    J Virol. 2024 Jan 30:e0200223. doi: 10.1128/jvi.02002.
    PubMed     Abstract available
    
    
    
22. DENG Y, Sheng Y, Zhang G, Sun Y, et al
    A novel strategy for an anti-idiotype vaccine: nanobody mimicking neutralization epitope of porcine circovirus type 2.
    J Virol. 2024 Jan 25:e0165023. doi: 10.1128/jvi.01650.
    PubMed     Abstract available
    
    
    
23. DULIN H, Barre RS, Xu D, Neal A, et al
    Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2.
    J Virol. 2024 Jan 11:e0157123. doi: 10.1128/jvi.01571.
    PubMed     Abstract available
    
    
    
24. TU JJ, King E, Maksimova V, Smith S, et al
    An HTLV-1 envelope mRNA vaccine is immunogenic and protective in New Zealand rabbits.
    J Virol. 2024 Jan 9:e0162323. doi: 10.1128/jvi.01623.
    PubMed     Abstract available
    
    
    
25. HE Y, Guo Z, Subiaur S, Benegal A, et al
    Antibody inhibition of influenza A virus assembly and release.
    J Virol. 2024 Jan 5:e0139823. doi: 10.1128/jvi.01398.
    PubMed     Abstract available
    
    
    
26. HSIEH W-S, Chao C-H, Shen C-Y, Cheng D, et al
    VP1 codon deoptimization and high-fidelity substitutions in 3D polymerase as potential vaccine strategies for eliciting immune responses against enterovirus A71.
    J Virol. 2024 Jan 4:e0155823. doi: 10.1128/jvi.01558.
    PubMed     Abstract available
    
    
    
27. VERDEJO-TORRES O, Vargas-Pavia T, Fatima S, Clapham PR, et al
    Implications of the 375W mutation for HIV-1 tropism and vaccine development.
    J Virol. 2024 Jan 3:e0152223. doi: 10.1128/jvi.01522.
    PubMed     Abstract available
    
    
    December 2023
28. XIAO X, Wen Z, Chen Q, Shipman JM, et al
    Structural characterization of M8C10, a neutralizing antibody targeting a highly conserved prefusion-specific epitope on the metapneumovirus fusion trimerization interface.
    J Virol. 2023;97:e0105223.
    PubMed     Abstract available
    
    
    
29. VUKOVICH MJ, Raju N, Kgagudi P, Manamela NP, et al
    Development of LIBRA-seq for the guinea pig model system as a tool for the evaluation of antibody responses to multivalent HIV-1 vaccines.
    J Virol. 2023 Dec 12:e0147823. doi: 10.1128/jvi.01478.
    PubMed     Abstract available
    
    
    
30. HAGA Y, Meyer K, Sung MMH, Reagan EK, et al
    Hepatitis C virus modified sE2(F442NYT) as an antigen in candidate vaccine facilitates human immune cell activation.
    J Virol. 2023 Dec 12:e0180923. doi: 10.1128/jvi.01809.
    PubMed     Abstract available
    
    
    
31. ZAYOU L, Prakash S, Dhanushkodi NR, Quadiri A, et al
    A multi-epitope/CXCL11 prime/pull coronavirus mucosal vaccine boosts the frequency and the function of lung-resident memory CD4(+) and CD8(+) T cells and enhanced protection against COVID-19-like symptoms and death caused by SARS-CoV-2 infection.
    J Virol. 2023 Dec 1:e0109623. doi: 10.1128/jvi.01096.
    PubMed     Abstract available
    
    
    November 2023
32. KEELAPANG P, Ketloy C, Puttikhunt C, Sriburi R, et al
    Heterologous prime-boost immunization induces protection against dengue virus infection in cynomolgus macaques.
    J Virol. 2023;97:e0096323.
    PubMed     Abstract available
    
    
    
33. RANATHUNGA L, Dodantenna N, Cha J-W, Chathuranga K, et al
    African swine fever virus B175L inhibits the type I interferon pathway by targeting STING and 2'3'-cGAMP.
    J Virol. 2023;97:e0079523.
    PubMed     Abstract available
    
    
    
34. ZHU X, Wang L, Gong L, Zhai Y, et al
    LORF9 of Marek's disease virus is involved in the early cytolytic replication of B lymphocyte and can act as a target for gene deletion vaccine development.
    J Virol. 2023 Nov 28:e0157423. doi: 10.1128/jvi.01574.
    PubMed     Abstract available
    
    
    
35. KAO C-F, Liu C-Y, Hsieh C-L, Carillo KJD, et al
    Structural and functional analyses of viral H2 protein of the vaccinia virus entry fusion complex.
    J Virol. 2023 Nov 17:e0134323. doi: 10.1128/jvi.01343.
    PubMed     Abstract available
    
    
    
36. NIU X, Liu M, Yang S, Xu J, et al
    A recombination-resistant genome for live attenuated and stable PEDV vaccines by engineering the transcriptional regulatory sequences.
    J Virol. 2023 Nov 16:e0119323. doi: 10.1128/jvi.01193.
    PubMed     Abstract available
    
    
    
37. ZENG R, Fu J, Pan W, Zhan Z, et al
    Low-temperature immunization attenuates the residual virulence of orf074r gene-deleted infectious spleen and kidney necrosis virus: a candidate immersion vaccine.
    J Virol. 2023 Nov 7:e0128923. doi: 10.1128/jvi.01289.
    PubMed     Abstract available
    
    
    
38. SUN W, Xu J, Wang Z, Li D, et al
    Clade 2.3.4.4 H5 chimeric cold-adapted attenuated influenza vaccines induced cross-reactive protection in mice and ferrets.
    J Virol. 2023 Nov 2:e0110123. doi: 10.1128/jvi.01101.
    PubMed     Abstract available
    
    
    
39. RIJNINK WF, Stadlbauer D, Puente-Massaguer E, Okba NMA, et al
    Characterization of non-neutralizing human monoclonal antibodies that target the M1 and NP of influenza A viruses.
    J Virol. 2023 Nov 2:e0164622. doi: 10.1128/jvi.01646.
    PubMed     Abstract available
    
    
    October 2023
40. HOU YN, Jin YQ, Zhang XF, Tang F, et al
    Chimeric virus-like particles of human norovirus constructed by structure-guided epitope grafting elicit cross-reactive immunity against both GI.1 and GII.4 genotypes.
    J Virol. 2023;97:e0093823.
    PubMed     Abstract available
    
    
    
41. WOOD ML, Neumann R, Roy P, Nair V, et al
    Characterization of integrated Marek's disease virus genomes supports a model of integration by homology-directed recombination and telomere-loop-driven excision.
    J Virol. 2023;97:e0071623.
    PubMed     Abstract available
    
    
    
42. BARTSCH YC, Cizmeci D, Yuan D, Mehta N, et al
    Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine.
    J Virol. 2023 Oct 30:e0077123. doi: 10.1128/jvi.00771.
    PubMed     Abstract available
    
    
    
43. HAO X, Li J, Wang J, Zhou Z, et al
    Co-administration of chicken IL-2 alleviates clinical signs and replication of the ILTV chicken embryo origin vaccine by pre-activating natural killer cells and cytotoxic T lymphocytes.
    J Virol. 2023 Oct 26:e0132223. doi: 10.1128/jvi.01322.
    PubMed     Abstract available
    
    
    
44. JOHNSON RM, Ardanuy J, Hammond H, Logue J, et al
    Diet-induced obesity and diabetes enhance mortality and reduce vaccine efficacy for SARS-CoV-2.
    J Virol. 2023 Oct 17:e0133623. doi: 10.1128/jvi.01336.
    PubMed     Abstract available
    
    
    
45. LI J, Zhao S, Zhang B, Huang J, et al
    A novel recombinant S-based subunit vaccine induces protective immunity against porcine deltacoronavirus challenge in piglets.
    J Virol. 2023 Oct 17:e0095823. doi: 10.1128/jvi.00958.
    PubMed     Abstract available
    
    
    
46. WU Y, Shi J, He X, Lu J, et al
    Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants.
    J Virol. 2023 Oct 16:e0127923. doi: 10.1128/jvi.01279.
    PubMed     Abstract available
    
    
    
47. MISPLON JA, Lo CY, Crabbs TA, Price GE, et al
    Adenoviral-vectored universal influenza vaccines administered intranasally reduce lung inflammatory responses upon viral challenge 15 months post-vaccination.
    J Virol. 2023 Oct 13:e0067423. doi: 10.1128/jvi.00674.
    PubMed     Abstract available
    
    
    
48. VAN DUIJN J, Stieh D, Fernandez N, King D, et al
    Mosaic HIV-1 vaccination induces anti-viral CD8(+) T cell functionality in the phase 1/2a clinical trial APPROACH.
    J Virol. 2023 Oct 9:e0112623. doi: 10.1128/jvi.01126.
    PubMed     Abstract available
    
    
    
49. MCMAHON M, Tan J, O'Dell G, Kirkpatrick Roubidoux E, et al
    Immunity induced by vaccination with recombinant influenza B virus neuraminidase protein breaks viral transmission chains in guinea pigs in an exposure intensity-dependent manner.
    J Virol. 2023 Oct 6:e0105723. doi: 10.1128/jvi.01057.
    PubMed     Abstract available
    
    
    September 2023
50. LI J, Song J, Zhou S, Li S, et al
    Development of a new effective African swine fever virus vaccine candidate by deletion of the H240R and MGF505-7R genes results in protective immunity against the Eurasia strain.
    J Virol. 2023 Sep 28:e0070423. doi: 10.1128/jvi.00704.
    PubMed     Abstract available
    
    
    
51. MCCOOL RS, Musayev M, Bush SM, Derrien-Colemyn A, et al
    Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein elicits antibodies targeting a membrane-proximal epitope.
    J Virol. 2023 Sep 22:e0092923. doi: 10.1128/jvi.00929.
    PubMed     Abstract available
    
    
    
52. PENG Q, Fan B, Song X, He W, et al
    Genetic signatures associated with the virulence of porcine epidemic diarrhea virus AH2012/12.
    J Virol. 2023 Sep 21:e0106323. doi: 10.1128/jvi.01063.
    PubMed     Abstract available
    
    
    
53. LAN W, Quan L, Li Y, Ou J, et al
    Isolation of novel simian adenoviruses from macaques for development of a vector for human gene therapy and vaccines.
    J Virol. 2023 Sep 15:e0101423. doi: 10.1128/jvi.01014.
    PubMed     Abstract available
    
    
    
54. XING M, Wang Y, Wang X, Liu J, et al
    Broad-spectrum vaccine via combined immunization routes triggers potent immunity to SARS-CoV-2 and its variants.
    J Virol. 2023 Sep 14:e0072423. doi: 10.1128/jvi.00724.
    PubMed     Abstract available
    
    
    
55. RAO PG, Lambert GS, Upadhyay C
    Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells.
    J Virol. 2023 Sep 8:e0071023. doi: 10.1128/jvi.00710.
    PubMed     Abstract available
    
    
    June 2023
56. ZENG R, Pan W, Lin Y, Liang M, et al
    A Safe and Efficient Double-Gene-Deleted Live Attenuated Immersion Vaccine to Prevent the Disease Caused by the Infectious Spleen and Kidney Necrosis Virus.
    J Virol. 2023 Jun 29:e0085723. doi: 10.1128/jvi.00857.
    PubMed     Abstract available
    
    
    
57. WU Q, Zhang Y, Wang C, Hou Y, et al
    Short-Chain Fatty Acids Alleviate Vancomycin-Caused Humoral Immunity Attenuation in Rabies-Vaccinated Mice by Promoting the Generation of Plasma Cells via Akt-mTOR Pathway.
    J Virol. 2023 Jun 20:e0065623. doi: 10.1128/jvi.00656.
    PubMed     Abstract available
    
    
    
58. GOFFIN E, Du X, Hemmi S, Machiels B, et al
    A Single Oral Immunization with a Replication-Competent Adenovirus-Vectored Vaccine Protects Mice from Influenza Respiratory Infection.
    J Virol. 2023 Jun 20:e0013523. doi: 10.1128/jvi.00135.
    PubMed     Abstract available
    
    
    May 2023
59. ZHU G, Ren J, Li D, Ru Y, et al
    Combinational Deletions of MGF110-9L and MGF505-7R Genes from the African Swine Fever Virus Inhibit TBK1 Degradation by an Autophagy Activator PIK3C2B To Promote Type I Interferon Production.
    J Virol. 2023;97:e0022823.
    PubMed     Abstract available
    
    
    
60. REZENDE W, Ye X, Angelo LS, Carisey AF, et al
    The Efficiency of p27 Cleavage during In Vitro Respiratory Syncytial Virus (RSV) Infection Is Cell Line and RSV Subtype Dependent.
    J Virol. 2023;97:e0025423.
    PubMed     Abstract available
    
    
    April 2023
61. SPATZ S, Garcia M, Fuchs W, Loncoman C, et al
    Reconstitution and Mutagenesis of Avian Infectious Laryngotracheitis Virus from Cosmid and Yeast Centromeric Plasmid Clones.
    J Virol. 2023;97:e0140622.
    PubMed     Abstract available
    
    
    
62. QI X, Feng T, Ma Z, Zheng L, et al
    Deletion of DP148R, DP71L, and DP96R Attenuates African Swine Fever Virus, and the Mutant Strain Confers Complete Protection against Homologous Challenges in Pigs.
    J Virol. 2023;97:e0024723.
    PubMed     Abstract available
    
    
    
63. SASTRY M, Changela A, Gorman J, Xu K, et al
    Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization.
    J Virol. 2023 Apr 26:e0160422. doi: 10.1128/jvi.01604.
    PubMed     Abstract available
    
    
    
64. FENG H, Yao L, Zeng Z, Jiang L, et al
    Identification of Embryonic Chicken Proteases Activating Newcastle Disease Virus and Their Roles in the Pathogenicity of Virus Used as In Ovo Vaccine.
    J Virol. 2023 Apr 12:e0032423. doi: 10.1128/jvi.00324.
    PubMed     Abstract available
    
    
    March 2023
65. GONG YM, Wei XF, Zheng YY, Li Y, et al
    Combining Phage Display Technology with In Silico-Designed Epitope Vaccine to Elicit Robust Antibody Responses against Emerging Pathogen Tilapia Lake Virus.
    J Virol. 2023 Mar 28:e0005023. doi: 10.1128/jvi.00050.
    PubMed     Abstract available
    
    
    
66. STAMOS JD, Rahman MA, Gorini G, Silva de Castro I, et al
    Effect of Passive Administration of Monoclonal Antibodies Recognizing Simian Immunodeficiency Virus (SIV) V2 in CH59-Like Coil/Helical or beta-Sheet Conformations on Time of SIV(mac251) Acquisition.
    J Virol. 2023 Mar 28:e0186422. doi: 10.1128/jvi.01864.
    PubMed     Abstract available
    
    
    
67. DESROSIERS RC
    The Failure of AIDS Vaccine Efficacy Trials: Where to Go from Here.
    J Virol. 2023 Mar 14:e0021123. doi: 10.1128/jvi.00211.
    PubMed     Abstract available
    
    
    
68. ABBO SR, Nguyen W, Abma-Henkens MHC, van de Kamer D, et al
    Comparative Efficacy of Mayaro Virus-Like Particle Vaccines Produced in Insect or Mammalian Cells.
    J Virol. 2023 Mar 8:e0160122. doi: 10.1128/jvi.01601.
    PubMed     Abstract available
    
    
    February 2023
69. WANG Y, Ge F, Wang J, Li H, et al
    Mycobacterium bovis BCG Given at Birth Followed by Inactivated Respiratory Syncytial Virus Vaccine Prevents Vaccine-Enhanced Disease by Promoting Trained Macrophages and Resident Memory T Cells.
    J Virol. 2023 Feb 13:e0176422. doi: 10.1128/jvi.01764.
    PubMed     Abstract available
    
    
    
70. AMANAT F, Clark J, Carreno JM, Strohmeier S, et al
    Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination.
    J Virol. 2023 Feb 13:e0166422. doi: 10.1128/jvi.01664.
    PubMed     Abstract available
    
    
    
71. KURIAKOSE GIFT S, Wieczorek L, Sanders-Buell E, Zemil M, et al
    Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies.
    J Virol. 2023 Feb 7:e0163522. doi: 10.1128/jvi.01635.
    PubMed     Abstract available
    
    
    January 2023
72. TJARNHAGE E, Brown D, Bogen B, Andersen TK, et al
    Trimeric, APC-Targeted Subunit Vaccines Protect Mice against Seasonal and Pandemic Influenza.
    J Virol. 2023 Jan 31:e0169422. doi: 10.1128/jvi.01694.
    PubMed     Abstract available
    
    
    
73. GILL AL, Hudson WH, Valanparambil RM, Ahn E, et al
    Longitudinal Analysis of the Phenotype, Transcriptional Profile, and Anatomic Location of Memory CD8 T Cell Subsets after Acute Viral Infection.
    J Virol. 2023;97:e0155622.
    PubMed     Abstract available
    
    
    
74. SAKABE S, Cubitt B, Martinez-Sobrido L, de la Torre JC, et al
    Molecular Engineering of a Mammarenavirus with Unbreachable Attenuation.
    J Virol. 2023;97:e0138522.
    PubMed     Abstract available
    
    
    
75. SHIWA-SUDO N, Sakai Y, Iwata-Yoshikawa N, Watanabe S, et al
    Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.
    J Virol. 2023 Jan 12:e0136622. doi: 10.1128/jvi.01366.
    PubMed     Abstract available
    
    
    
76. MCGINNES CULLEN L, Luo B, Wen Z, Zhang L, et al
    The Respiratory Syncytial Virus (RSV) G Protein Enhances the Immune Responses to the RSV F Protein in an Enveloped Virus-Like Particle Vaccine Candidate.
    J Virol. 2023 Jan 5:e0190022. doi: 10.1128/jvi.01900.
    PubMed     Abstract available
    
    
    December 2022
77. DELVA JL, Daled S, Van Waesberghe C, Almey R, et al
    Proteomic Comparison of Three Wild-Type Pseudorabies Virus Strains and the Attenuated Bartha Strain Reveals Reduced Incorporation of Several Tegument Proteins in Bartha Virions.
    J Virol. 2022;96:e0115822.
    PubMed     Abstract available
    
    
    
78. GOUMA S, Furey C, Santos JJS, Parkhouse K, et al
    Nucleoside-Modified mRNA-Based Influenza Vaccines Circumvent Problems Associated with H3N2 Vaccine Strain Egg Adaptation.
    J Virol. 2022 Dec 19:e0172322. doi: 10.1128/jvi.01723.
    PubMed     Abstract available
    
    
    
79. MEADE P, Strohmeier S, Bermudez-Gonzalez MC, Garcia-Sastre A, et al
    Antigenic Landscape Analysis of Individuals Vaccinated with a Universal Influenza Virus Vaccine Candidate Reveals Induction of Cross-Subtype Immunity.
    J Virol. 2022 Dec 19:e0107022. doi: 10.1128/jvi.01070.
    PubMed     Abstract available
    
    
    November 2022
80. STEPHENS LM, Ross KA, McLellan JS, Narasimhan B, et al
    Long-Lasting Protection Induced by a Polyanhydride Nanovaccine against Respiratory Syncytial Virus in an Outbred Mouse Model.
    J Virol. 2022;96:e0150222.
    PubMed     Abstract available
    
    
    
81. PHILIP AA, Patton JT
    Generation of Recombinant Rotaviruses Expressing Human Norovirus Capsid Proteins.
    J Virol. 2022;96:e0126222.
    PubMed     Abstract available
    
    
    
82. HARWOOD OE, Balgeman AJ, Weaver AJ, Ellis-Connell AL, et al
    Transient T Cell Expansion, Activation, and Proliferation in Therapeutically Vaccinated Simian Immunodeficiency Virus-Positive Macaques Treated with N-803.
    J Virol. 2022 Nov 15:e0142422. doi: 10.1128/jvi.01424.
    PubMed     Abstract available
    
    
    October 2022
83. BRICE AM, Rozario AM, Rawlinson SM, David CT, et al
    Lyssavirus P Protein Isoforms Diverge Significantly in Subcellular Interactions Underlying Mechanisms of Interferon Antagonism.
    J Virol. 2022;96:e0139622.
    PubMed     Abstract available
    
    
    
84. DING M, Dang W, Liu H, Zhang K, et al
    Sequential Deletions of Interferon Inhibitors MGF110-9L and MGF505-7R Result in Sterile Immunity against the Eurasia Strain of Africa Swine Fever.
    J Virol. 2022;96:e0119222.
    PubMed     Abstract available
    
    
    
85. ELLIS-CONNELL AL, Balgeman AJ, Harwood OE, Moriarty RV, et al
    Control of Simian Immunodeficiency Virus Infection in Prophylactically Vaccinated, Antiretroviral Treatment-Naive Macaques Is Required for the Most Efficacious CD8 T Cell Response during Treatment with the Interleukin-15 Superagonist N-803.
    J Virol. 2022 Oct 3:e0118522. doi: 10.1128/jvi.01185.
    PubMed     Abstract available
    
    
    
86. BONIFACIO JPPL, Williams N, Garnier L, Hugues S, et al
    Optimizing the Live Attenuated Influenza A Vaccine Backbone for High-Risk Patient Groups.
    J Virol. 2022 Oct 3:e0087122. doi: 10.1128/jvi.00871.
    PubMed     Abstract available
    
    
    September 2022
87. CHABOT S, Gimie Y, Obeid K, Kim J, et al
    Enhanced In Vitro and In Vivo Potency of a T Cell Epitope in the Ebola Virus Glycoprotein Following Amino Acid Replacement at HLA-A*02:01 Binding Positions.
    J Virol. 2022;96:e0116621.
    PubMed     Abstract available
    
    
    
88. REDDY VRAP, Nazki S, Brodrick AJ, Asfor A, et al
    Evaluating the Breadth of Neutralizing Antibody Responses Elicited by Infectious Bursal Disease Virus Genogroup A1 Strains Using a Novel Chicken B-Cell Rescue System and Neutralization Assay.
    J Virol. 2022;96:e0125522.
    PubMed     Abstract available
    
    
    
89. DU Q, Yang X, Ma M, Zhang Q, et al
    The gC1qR Binding Site Mutant PCV2 Is a Potential Vaccine Strain That Does Not Impair Memory CD4(+) T-Cell Generation by Vaccines.
    J Virol. 2022 Sep 19:e0095922. doi: 10.1128/jvi.00959.
    PubMed     Abstract available
    
    
    
90. SIA ZR, Chiem K, Huang WC, Seffouh A, et al
    Respiratory Vaccination with Hemagglutinin Nanoliposomes Protects Mice from Homologous and Heterologous Strains of Influenza Virus.
    J Virol. 2022 Sep 15:e0100622. doi: 10.1128/jvi.01006.
    PubMed     Abstract available
    
    
    
91. AO Z, Ouyang MJ, Olukitibi TA, Warner B, et al
    A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection.
    J Virol. 2022 Sep 7:e0133722. doi: 10.1128/jvi.01337.
    PubMed     Abstract available
    
    
    August 2022
92. SHEN W, Wang Q, Wang Z, Liu M, et al
    Specific Monoclonal Antibodies Targeting Unique HA Epitopes Block H7N9 Influenza A Viral Replication.
    J Virol. 2022 Aug 29:e0123822. doi: 10.1128/jvi.01238.
    PubMed     Abstract available
    
    
    
93. FILES JK, Sterrett S, Henostroza S, Fucile C, et al
    HLA-II-Associated HIV-1 Adaptation Decreases CD4(+) T-Cell Responses in HIV-1 Vaccine Recipients.
    J Virol. 2022 Aug 24:e0119122. doi: 10.1128/jvi.01191.
    PubMed     Abstract available
    
    
    
94. NEERUKONDA SN, Wang R, Vassell R, Baha H, et al
    Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.
    J Virol. 2022 Aug 24:e0114022. doi: 10.1128/jvi.01140.
    PubMed     Abstract available
    
    
    
95. GUPTA SL, Mantus G, Manning KE, Ellis M, et al
    Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults.
    J Virol. 2022 Aug 17:e0058222. doi: 10.1128/jvi.00582.
    PubMed     Abstract available
    
    
    
96. KEEP S, Stevenson-Leggett P, Dowgier G, Foldes K, et al
    A Temperature-Sensitive Recombinant of Avian Coronavirus Infectious Bronchitis Virus Provides Complete Protection against Homologous Challenge.
    J Virol. 2022 Aug 16:e0110022. doi: 10.1128/jvi.01100.
    PubMed     Abstract available
    
    
    
97. SHI J, Zheng J, Tai W, Verma AK, et al
    A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    J Virol. 2022 Aug 16:e0011822. doi: 10.1128/jvi.00118.
    PubMed     Abstract available
    
    
    
98. VERMILLION MS, Dearing J, Zhang Y, Adney DR, et al
    Animal Models of Enterovirus D68 Infection and Disease.
    J Virol. 2022;96:e0083322.
    PubMed     Abstract available
    
    
    
99. DODANTENNA N, Ranathunga L, Chathuranga WAG, Weerawardhana A, et al
    African Swine Fever Virus EP364R and C129R Target Cyclic GMP-AMP To Inhibit the cGAS-STING Signaling Pathway.
    J Virol. 2022;96:e0102222.
    PubMed     Abstract available
    
    
    
100. CHAN M, Tiwary M, Wu HL, Tailor N, et al
     Pandemic 1918 Influenza Virus Does Not Cause Lethal Infection in Rhesus or Cynomolgus Macaques.
     J Virol. 2022 Aug 4:e0072822. doi: 10.1128/jvi.00728.
     PubMed     Abstract available
     
     
     
101. ABBADI N, Nagashima K, Pena-Briseno A, Ross TM, et al
     Differential Recognition of Computationally Optimized H3 Hemagglutinin Influenza Vaccine Candidates by Human Antibodies.
     J Virol. 2022 Aug 2:e0089622. doi: 10.1128/jvi.00896.
     PubMed     Abstract available
     
     
     
102. YUAN M, Chen X, Zhu Y, Dong X, et al
     A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
     J Virol. 2022 Aug 2:e0077522. doi: 10.1128/jvi.00775.
     PubMed     Abstract available
     
     
     July 2022
103. DING M, Dang W, Liu H, Xu F, et al
     Combinational Deletions of MGF360-9L and MGF505-7R Attenuated Highly Virulent African Swine Fever Virus and Conferred Protection against Homologous Challenge.
     J Virol. 2022;96:e0032922.
     PubMed     Abstract available
     
     
     
104. VUONO E, Ramirez-Medina E, Silva E, Rai A, et al
     Deletion of the H108R Gene Reduces Virulence of the Pandemic Eurasia Strain of African Swine Fever Virus with Surviving Animals Being Protected against Virulent Challenge.
     J Virol. 2022;96:e0054522.
     PubMed     Abstract available
     
     
     
105. WANG M, Bohorquez JA, Munoz-Gonzalez S, Gerber M, et al
     Removal of the E(rns) RNase Activity and of the 3' Untranslated Region Polyuridine Insertion in a Low-Virulence Classical Swine Fever Virus Triggers a Cytokine Storm and Lethal Disease.
     J Virol. 2022;96:e0043822.
     PubMed     Abstract available
     
     
     
106. PUSNIK J, Konig J, Mai K, Richter E, et al
     Persistent Maintenance of Intermediate Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response.
     J Virol. 2022 Jul 12:e0076022. doi: 10.1128/jvi.00760.
     PubMed     Abstract available
     
     
     
107. CHAPARIAN RR, Harding AT, Hamele CE, Riebe K, et al
     A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice.
     J Virol. 2022 Jul 12:e0068922. doi: 10.1128/jvi.00689.
     PubMed     Abstract available
     
     
     
108. RAMIREZ-MEDINA E, Vuono E, Silva E, Rai A, et al
     Evaluation of the Deletion of MGF110-5L-6L on Swine Virulence from the Pandemic Strain of African Swine Fever Virus and Use as a DIVA Marker in Vaccine Candidate ASFV-G-DeltaI177L.
     J Virol. 2022 Jul 11:e0059722. doi: 10.1128/jvi.00597.
     PubMed     Abstract available
     
     
     
109. VAN DE VEN K, van Dijken H, Du W, de Heij F, et al
     Varying Viral Replication and Disease Profiles of H2N2 Influenza in Ferrets Is Associated with Virus Isolate and Inoculation Route.
     J Virol. 2022 Jul 11:e0073222. doi: 10.1128/jvi.00732.
     PubMed     Abstract available
     
     
     June 2022
110. VAN OOSTEN L, Yan K, Rawle DJ, Le TT, et al
     An S1-Nanoparticle Vaccine Protects against SARS-CoV-2 Challenge in K18-hACE2 Mice.
     J Virol. 2022 Jun 29:e0084422. doi: 10.1128/jvi.00844.
     PubMed    
     
     
     
111. SHEWARD DJ, Hermanus T, Murrell B, Garrett N, et al
     HIV Coinfection Provides Insights for the Design of Vaccine Cocktails to Elicit Broadly Neutralizing Antibodies.
     J Virol. 2022 Jun 27:e0032422. doi: 10.1128/jvi.00324.
     PubMed     Abstract available
     
     
     
112. KIM A, Lee G, Hwang JH, Park JH, et al
     BacMam Expressing Highly Glycosylated Porcine Interferon Alpha Induces Robust Antiviral and Adjuvant Effects against Foot-and-Mouth Disease Virus in Pigs.
     J Virol. 2022;96:e0052822.
     PubMed     Abstract available
     
     
     
113. OLCZAK P, Matsui K, Wong M, Alvarez J, et al
     RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer.
     J Virol. 2022 Jun 15:e0056622. doi: 10.1128/jvi.00566.
     PubMed     Abstract available
     
     
     
114. SUN C, Yuan RY, Xie C, Sun JF, et al
     Induction of Broadly Cross-Reactive Antibody Responses to SARS-CoV-2 Variants by S1 Nanoparticle Vaccines.
     J Virol. 2022 Jun 14:e0038322. doi: 10.1128/jvi.00383.
     PubMed     Abstract available
     
     
     
115. LIN J, Law R, Korosec CS, Zhou C, et al
     Longitudinal Assessment of SARS-CoV-2-Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multicytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity.
     J Virol. 2022 Jun 14:e0050922. doi: 10.1128/jvi.00509.
     PubMed     Abstract available
     
     
     
116. CHEN X, Li J, Yang L, Zhou Y, et al
     Immunoglobin G Sero-Dynamics Aided Host Specific Linear Epitope Identification and Differentiation of Infected from Vaccinated Hosts.
     J Virol. 2022 Jun 6:e0014322. doi: 10.1128/jvi.00143.
     PubMed     Abstract available
     
     
     May 2022
117. PRICE GE, Lo CY, Misplon JA, Epstein SL, et al
     Reduction of Influenza A Virus Transmission in Mice by a Universal Intranasal Vaccine Candidate is Long-Lasting and Does Not Require Antibodies.
     J Virol. 2022 May 31:e0032022. doi: 10.1128/jvi.00320.
     PubMed     Abstract available
     
     
     
118. DELVA JL, Van Waesberghe C, Van Den Broeck W, Lamote JA, et al
     The Attenuated Pseudorabies Virus Vaccine Strain Bartha Hyperactivates Plasmacytoid Dendritic Cells by Generating Large Amounts of Cell-Free Virus in Infected Epithelial Cells.
     J Virol. 2022 May 23:e0219921. doi: 10.1128/jvi.02199.
     PubMed     Abstract available
     
     
     
119. VANDOORN E, Stadejek W, Parys A, Chepkwony S, et al
     Pathobiology of an NS1-Truncated H3N2 Swine Influenza Virus Strain in Pigs.
     J Virol. 2022 May 12:e0051922. doi: 10.1128/jvi.00519.
     PubMed     Abstract available
     
     
     
120. LINVILLE AC, Rico AB, Teague H, Binsted LE, et al
     Dysregulation of Cellular VRK1, BAF, and Innate Immune Signaling by the Vaccinia Virus B12 Pseudokinase.
     J Virol. 2022 May 11:e0039822. doi: 10.1128/jvi.00398.
     PubMed     Abstract available
     
     
     
121. LUCAS CJ, Davenport BJ, Carpentier KS, Tinega AN, et al
     Two Conserved Phenylalanine Residues in the E1 Fusion Loop of Alphaviruses Are Essential for Viral Infectivity.
     J Virol. 2022;96:e0006422.
     PubMed     Abstract available
     
     
     
122. TU JJ, Kumar A, Giorgi EE, Eudailey J, et al
     Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses.
     J Virol. 2022 May 10:e0023122. doi: 10.1128/jvi.00231.
     PubMed     Abstract available
     
     
     April 2022
123. MANTLO EK, Maruyama J, Manning JT, Wanninger TG, et al
     Machupo Virus with Mutations in the Transmembrane Domain and Glycosylation Sites of the Glycoprotein Is Attenuated and Immunogenic in Animal Models of Bolivian Hemorrhagic Fever.
     J Virol. 2022;96:e0020922.
     PubMed     Abstract available
     
     
     
124. KIRKPATRICK ROUBIDOUX E, Sano K, McMahon M, Carreno JM, et al
     Novel Epitopes of the Influenza Virus N1 Neuraminidase Targeted by Human Monoclonal Antibodies.
     J Virol. 2022 Apr 21:e0033222. doi: 10.1128/jvi.00332.
     PubMed     Abstract available
     
     
     
125. NUNEZ CASTREJON AM, O'Rourke SM, Kauvar LM, DuBois RM, et al
     Structure-Based Design and Antigenic Validation of Respiratory Syncytial Virus G Immunogens.
     J Virol. 2022;96:e0220121.
     PubMed     Abstract available
     
     
     
126. DESCHAMBAULT Y, Lynch J, Warner B, Tierney K, et al
     Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
     J Virol. 2022 Apr 12:e0038922. doi: 10.1128/jvi.00389.
     PubMed     Abstract available
     
     
     
127. TEMPLETON CW, Traktman P
     UV Irradiation of Vaccinia Virus-Infected Cells Impairs Cellular Functions, Introduces Lesions into the Viral Genome, and Uncovers Repair Capabilities for the Viral Replication Machinery.
     J Virol. 2022 Apr 11:e0213721. doi: 10.1128/jvi.02137.
     PubMed     Abstract available
     
     
     
128. KONG XW, Zhang X, Bu GL, Xu HQ, et al
     Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses.
     J Virol. 2022 Apr 11:e0033622. doi: 10.1128/jvi.00336.
     PubMed     Abstract available
     
     
     
129. BRIGGS K, Kirby C, Beavis AC, Zengel J, et al
     Immunogenicity of Mumps Virus Genotype G Vaccine Candidates in Jeryl Lynn-Immunized Mice.
     J Virol. 2022 Apr 7:e0198321. doi: 10.1128/jvi.01983.
     PubMed     Abstract available
     
     
     
130. FARIAS JP, da Silva PS, Fogaca MMC, Santana IVR, et al
     The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine.
     J Virol. 2022 Apr 7:e0017722. doi: 10.1128/jvi.00177.
     PubMed     Abstract available
     
     
     
131. KLASSE PJ, Moore JP
     Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses.
     J Virol. 2022 Apr 6:e0003422. doi: 10.1128/jvi.00034.
     PubMed     Abstract available
     
     
     March 2022
132. LIU MQ, Jiang RD, Guo J, Chen Y, et al
     Inactivated SARS-CoV-2 Vaccine Shows Cross-Protection against Bat SARS-Related Coronaviruses in Human ACE2 Transgenic Mice.
     J Virol. 2022 Mar 28:e0016922. doi: 10.1128/jvi.00169.
     PubMed     Abstract available
     
     
     
133. NGUYEN HT, Qualizza A, Anang S, Zhao M, et al
     Functional and Highly Cross-Linkable HIV-1 Envelope Glycoproteins Enriched in a Pretriggered Conformation.
     J Virol. 2022 Mar 28:e0166821. doi: 10.1128/jvi.01668.
     PubMed     Abstract available
     
     
     
134. EICHHOLZ K, Tran TH, Cheneau C, Tran TTP, et al
     Adenovirus-alpha-Defensin Complexes Induce NLRP3-Associated Maturation of Human Phagocytes via Toll-Like Receptor 4 Engagement.
     J Virol. 2022;96:e0185021.
     PubMed     Abstract available
     
     
     
135. RATHAKRISHNAN A, Connell S, Petrovan V, Moffat K, et al
     Differential Effect of Deleting Members of African Swine Fever Virus Multigene Families 360 and 505 from the Genotype II Georgia 2007/1 Isolate on Virus Replication, Virulence, and Induction of Protection.
     J Virol. 2022;96:e0189921.
     PubMed     Abstract available
     
     
     
136. CHEN SMY, Wong YC, Yim LY, Zhang H, et al
     Enhanced Cross-Reactive and Polyfunctional Effector-Memory T Cell Responses by ICVAX-a Human PD1-Based Bivalent HIV-1 Gag-p41 Mosaic DNA Vaccine.
     J Virol. 2022 Mar 17:e0216121. doi: 10.1128/jvi.02161.
     PubMed     Abstract available
     
     
     
137. ALLEN JD, Ross TM
     Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.
     J Virol. 2022 Mar 15:e0165221. doi: 10.1128/jvi.01652.
     PubMed     Abstract available
     
     
     February 2022
138. ELSAYED H, Nabi G, McKinstry WJ, Khoo KK, et al
     Correction for Elsayed et al., "Intrastructural Help: Harnessing T Helper Cells Induced by Licensed Vaccines for Improvement of HIV Env Antibody Responses to Virus-Like Particle Vaccines".
     J Virol. 2022;96:e0195421.
     PubMed    
     
     
     
139. UTRILLA-TRIGO S, Jimenez-Cabello L, Calvo-Pinilla E, Marin-Lopez A, et al
     The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS21-180) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge.
     J Virol. 2022;96:e0161421.
     PubMed     Abstract available
     
     
     
140. ZHANG YN, Zhang ZR, Li N, Pei XR, et al
     High titer self-propagating capsidless Chikungunya virus generated in Vero cells as a strategy for alphavirus vaccine development.
     J Virol. 2022 Feb 2:JVI0148021. doi: 10.1128/JVI.01480.
     PubMed     Abstract available
     
     
     
141. ROSU ME, Kok A, Bestebroer TM, de Meulder D, et al
     Contribution of neuraminidase to the efficacy of seasonal split influenza vaccines in the ferret model.
     J Virol. 2022 Feb 2:jvi0195921. doi: 10.1128/jvi.01959.
     PubMed     Abstract available
     
     
     January 2022
142. LI Y, Yuan M, Han Y, Xie L, et al
     The Unique Glycosylation at Position 986 on the E2 Glycoprotein of Classical Swine Fever Virus Is Responsible for Viral Attenuation and Protection against Lethal Challenge.
     J Virol. 2022;96:e0176821.
     PubMed     Abstract available
     
     
     
143. GMYREK GB, Predki P, Gershburg E, Carr DJJ, et al
     Noncognate Signals Drive Enhanced Effector CD8(+) T Cell Responses through an IFNAR1-Dependent Pathway after Infection with the Prototypic Vaccine, 0DeltaNLS, against Herpes Simplex Virus 1.
     J Virol. 2022 Jan 19:JVI0172421. doi: 10.1128/JVI.01724.
     PubMed     Abstract available
     
     
     
144. KEEP S, Stevenson-Leggett P, Dowgier G, Everest H, et al
     Identification of amino acids within non-structural proteins 10 and 14 of the avian coronavirus infectious bronchitis virus that result in attenuation in vivo and in ovo.
     J Virol. 2022 Jan 19:jvi0205921. doi: 10.1128/jvi.02059.
     PubMed     Abstract available
     
     
     
145. PETROVAN V, Rathakrishnan A, Islam M, Goatley LC, et al
     Role of African Swine Fever Virus Proteins EP153R and EP402R in Reducing Viral Persistence in Blood and Virulence in Pigs Infected with BeninDeltaDP148R.
     J Virol. 2022;96:e0134021.
     PubMed     Abstract available
     
     
     
146. KIMBLE JB, Wymore Brand M, Kaplan BS, Gauger P, et al
     Vaccine-associated enhanced respiratory disease following influenza virus infection in ferrets recapitulates the model in pigs.
     J Virol. 2022 Jan 5:JVI0172521. doi: 10.1128/JVI.01725.
     PubMed     Abstract available
     
     
     
147. MCGREGOR J, Hardy JM, Lay CS, Boo I, et al
     Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs.
     J Virol. 2022 Jan 5:JVI0167521. doi: 10.1128/JVI.01675.
     PubMed     Abstract available
     
     
     December 2021
148. HUANG Y, Skarlupka AL, Jang H, Blas-Machado U, et al
     SARS-CoV-2 and Influenza A virus Co-infections in Ferrets.
     J Virol. 2021 Dec 22:JVI0179121. doi: 10.1128/JVI.01791.
     PubMed     Abstract available
     
     
     
149. CAO K, Wang X, Peng H, Ding L, et al
     A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice.
     J Virol. 2021 Dec 15:JVI0157821. doi: 10.1128/JVI.01578.
     PubMed     Abstract available
     
     
     
150. MUCKER EM, Golden JW, Hammerbeck CD, Kishimori JM, et al
     A nucleic acid-based orthopoxvirus vaccine targeting the vaccinia virus L1, A27, B5 and A33 proteins protects rabbits against lethal rabbitpox virus aerosol challenge.
     J Virol. 2021 Dec 1:JVI0150421. doi: 10.1128/JVI.01504.
     PubMed     Abstract available
     
     
     November 2021
151. WU C, He Y, Zhao J, Luo K, et al
     Exacerbated AIDS progression by PD-1 blockade during therapeutic vaccination in chronically SIV-infected rhesus macaques after ART treatment interruption.
     J Virol. 2021 Nov 24:JVI0178521. doi: 10.1128/JVI.01785.
     PubMed     Abstract available
     
     
     
152. APPELBERG S, John L, Pardi N, Vegvari A, et al
     Nucleoside-modified mRNA vaccines protect IFNAR(-/-) mice against Crimean Congo hemorrhagic fever virus infection.
     J Virol. 2021 Nov 24:JVI0156821. doi: 10.1128/JVI.01568.
     PubMed     Abstract available
     
     
     
153. BURCKHARDT RM, Dennehy JJ, Poon LLM, Saif LJ, et al
     Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters.
     J Virol. 2021 Nov 24:JVI0197321. doi: 10.1128/JVI.01973.
     PubMed     Abstract available
     
     
     
154. ZHANG H, Zheng H, Guo P, Hu L, et al
     Correction for Zhang et al., "Broadly Protective CD8(+) T Cell Immunity to Highly Conserved Epitopes Elicited by Heat Shock Protein gp96-Adjuvanted Influenza Monovalent Split Vaccine".
     J Virol. 2021;95:e0175021.
     PubMed    
     
     
     
155. SOUZA CK, Anderson TK, Chang J, Venkatesh D, et al
     Antigenic distance between North American swine and human seasonal H3N2 influenza A viruses as an indication of zoonotic risk to humans.
     J Virol. 2021 Nov 10:JVI0137421. doi: 10.1128/JVI.01374.
     PubMed     Abstract available
     
     
     
156. VANBLARGAN LA, Milutinovic PS, Goo L, DeMaso CR, et al
     Dengue Virus Serotype 1 Conformational Dynamics Confers Virus Strain-Dependent Patterns of Neutralization by Polyclonal Sera.
     J Virol. 2021;95:e0095621.
     PubMed     Abstract available
     
     
     
157. ZHANG Y, Ke J, Zhang J, Yang J, et al
     African Swine Fever Virus Bearing an I226R Gene Deletion Elicits Robust Immunity in Pigs to African Swine Fever.
     J Virol. 2021;95:e0119921.
     PubMed     Abstract available
     
     
     
158. MIELKE D, Stanfield-Oakley S, Borate B, Fisher LH, et al
     Selection of HIV Envelope strains for standardized assessments of vaccine-elicited antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies.
     J Virol. 2021 Nov 3:JVI0164321. doi: 10.1128/JVI.01643.
     PubMed     Abstract available
     
     
     
159. CARTEN JD, Greseth M, Traktman P
     Structure-function analysis of two interacting vaccinia proteins that are critical for viral morphogenesis: L2 and A30.5.
     J Virol. 2021 Nov 3:JVI0157721. doi: 10.1128/JVI.01577.
     PubMed     Abstract available
     
     
     October 2021
160. YU J, Collins ND, Mercado NB, McMahan K, et al
     Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery Against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques.
     J Virol. 2021 Oct 27:JVI0159921. doi: 10.1128/JVI.01599.
     PubMed     Abstract available
     
     
     
161. SCHORCHT A, Cottrell CA, Pugach P, Ringe RP, et al
     The glycan hole area of HIV-1 envelope trimers contributes prominently to the induction of autologous neutralization.
     J Virol. 2021 Oct 20:JVI0155221. doi: 10.1128/JVI.01552.
     PubMed     Abstract available
     
     
     
162. BELTRAN-PAVEZ C, Bontjer I, Gonzalez N, Pernas M, et al
     Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle (VLP) Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
     J Virol. 2021 Oct 20:JVI0134321. doi: 10.1128/JVI.01343.
     PubMed     Abstract available
     
     
     
163. GLADUE DP, Ramirez-Medina E, Vuono E, Silva E, et al
     Deletion of the A137R Gene from the Pandemic Strain of African Swine Fever Virus Attenuates the Strain and Offers Protection against the Virulent Pandemic Virus.
     J Virol. 2021;95:e0113921.
     PubMed     Abstract available
     
     
     
164. GAO J, Klenow L, Parsons L, Malik T, et al
     Design of the Recombinant Influenza Neuraminidase Antigen is Crucial for its Biochemical Properties and Protective Efficacy.
     J Virol. 2021 Oct 6:JVI0116021. doi: 10.1128/JVI.01160.
     PubMed     Abstract available
     
     
     
165. CHEN C, Zhang C, Li H, Wang Z, et al
     TLR4 regulates rabies virus-induced humoral immunity through recruitment of cDC2 to lymph organs.
     J Virol. 2021 Oct 6:JVI0082921. doi: 10.1128/JVI.00829.
     PubMed     Abstract available
     
     
     September 2021
166. SIEGERS JY, Dhanasekaran V, Xie R, Deng YM, et al
     Genetic and Antigenic Characterization of an Influenza A(H3N2) Outbreak in Cambodia and the Greater Mekong Subregion during the COVID-19 Pandemic, 2020.
     J Virol. 2021 Sep 29:JVI0126721. doi: 10.1128/JVI.01267.
     PubMed     Abstract available
     
     
     
167. CHOI A, Koch M, Wu K, Dixon G, et al
     Serum Neutralizing Activity of mRNA-1273 Against SARS-CoV-2 Variants.
     J Virol. 2021 Sep 22:JVI0131321. doi: 10.1128/JVI.01313.
     PubMed     Abstract available
     
     
     
168. KIRCHENBAUM GA, Sautto GA, Richardson RA, Ecker JW, et al
     A competitive hemagglutination inhibition assay for dissecting functional antibody activity to influenza virus.
     J Virol. 2021 Sep 15:JVI0237920. doi: 10.1128/JVI.02379.
     PubMed     Abstract available
     
     
     July 2021
169. DONG H, Lu Y, Zhang Y, Mu S, et al
     A Heat-Induced Mutation on VP1 of Foot-and-Mouth Disease Virus Serotype O Enhanced Capsid Stability and Immunogenicity.
     J Virol. 2021;95:e0017721.
     PubMed     Abstract available
     
     
     June 2021
170. VAN HAAREN MM, McCoy LE, Torres JL, Lee W, et al
     Antibodies from rabbits immunized with HIV-1 clade B SOSIP trimers can neutralize multiple clade B viruses by destabilizing the envelope glycoprotein.
     J Virol. 2021 Jun 2:JVI0009421. doi: 10.1128/JVI.00094.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.